Australia, Jan. 15 -- Azurity Pharmaceuticals Inc., owns the trademark (2576897) for 'AZURITY' till June 16, 2035.

Status: protected: Registered/protected

Classes: 5 [Pharmaceutical preparations sold as a kit for use by pharmacists and physicians in creating compounded hormone replacement medicines, topical anti-inflammatory and ultrasound gels, pain and gastrointestinal disorders treatment medicines, and anti-inflammatory, antimicrobial, and antifungal treatment medicines; medicines for the treatment of cardiovascular diseases and disorders, colitis, muscle spasm, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; antibiotics; pharmaceutical products for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders having vancomycin, enalapril, lisinopril, and methotrexate as the active pharmaceutical ingredient; antacids; muscle relaxants; hormone replacement medicines; topical anti-inflammatory and ultrasound gels; pharmaceutical preparation for the treatment of pain, thyroid disorders, gastrointestinal disorders, gastroesophageal disorders, inflammation, infections, fungal diseases and disorders, cardiovascular diseases and disorders, colitis, muscle spasm, attention deficit hyperactivity disorders, infectious diseases, acid-reflux disease, ulcer disease, and urological disorders; pharmaceuticals for use in the treatment of cancer and autoimmune diseases and disorders, and for the treatment and prevention of renal, oncological, inflammatory, gastrointestinal, gastroesophageal, and cardio-vascular diseases and disorders; pharmaceuticals for use in the treatment and prevention of respiratory, immunology, endocrinology, allergy diseases and disorders; imaging agents.] and 05 [pharmaceuticals for use in the treatment and prevention of respiratory, immunology, endocrinology, allergy diseases and disorders; imaging agents]

Type of Mark: Word

Date of Acceptance: Aug. 22, 2025

Registration Advertised: Jan. 14

For further details contact Greenfield & Sacks P.C. Douglas R. Wolf Wolf.

The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2576897.

Disclaimer: Curated by HT Syndication.